Log in

6955 Shandong Boan Biotechnology Company., Limited. HKEX · China

Shandong Boan Biotechnology Company., Limited. (6955) news

Shandong Boan Biotechnology Company., Limited. is a public biotech or pharmaceutical company listed on HKEX under the ticker 6955, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Shandong Boan Biotechnology Company., Limited. news

We have not published a story on Shandong Boan Biotechnology Company., Limited. yet. When there is news, it will appear here.

Questions about Shandong Boan Biotechnology Company., Limited.

What is the ticker symbol of Shandong Boan Biotechnology Company., Limited.?

Shandong Boan Biotechnology Company., Limited. trades under the ticker 6955 on HKEX.

Where is Shandong Boan Biotechnology Company., Limited. listed?

Shandong Boan Biotechnology Company., Limited. is listed on HKEX.

Which country or territory is Shandong Boan Biotechnology Company., Limited. listed under?

Our directory records Shandong Boan Biotechnology Company., Limited. under China.

What does Shandong Boan Biotechnology Company., Limited. do?

Our directory classifies Shandong Boan Biotechnology Company., Limited. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Shandong Boan Biotechnology Company., Limited.?

The ISIN recorded for Shandong Boan Biotechnology Company., Limited. is CNE100005RV4.

Does aibio.space cover Shandong Boan Biotechnology Company., Limited.?

aibio.space lists Shandong Boan Biotechnology Company., Limited. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Shandong Boan Biotechnology Company., Limited.?

Companies in our directory listed in the same country and business area as Shandong Boan Biotechnology Company., Limited.: Northeast Pharmaceutical Group Co., Nanjing Hicin Pharmaceutical Co., Jiangsu Yahong Meditech Co., Tianjin Chase Sun Pharmaceutical Co., Shanghai Allist Pharmaceuticals Co., Hunan Jiudian Pharmaceutical Co..

Investor discussion: Shandong Boan Biotechnology Company., Limited.

Members talk about Shandong Boan Biotechnology Company., Limited. (6955). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Shandong Boan Biotechnology Company., Limited., newest first. Each line links the filing it comes from.

  1. Mergers

    Transaction under the Listing Rules: SUPPLEMENTAL AGREEMENT IN RELATION TO DISCLOSEABLE TRANSACTION FINANCE LEASE AGREEMENT. Source

  2. Mergers

    Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION FINANCE LEASE AGREEMENT. Source

  3. Financings

    Share or debt issue: (1) 2025 REPORT OF THE BOARD OF DIRECTORS (2) 2025 REPORT OF THE BOARD OF SUPERVISORS (3) 2025 ANNUAL REPORT (4) RE-APPOINTMENT OF AUDITOR (5) REMUNERATION OF DIRECTORS (6) REMUNERATION OF SUPERVISORS (7) GENERAL MANDATE TO ISSUE ADDITIONAL SHARES (8) GENERAL MANDATE TO REPURCHASE SHARES (9) PROPOSED ADOPTION OF THE RSU INCENTIVE SCHEME AND PROPOSED AUTHORISATION TO THE BOARD AND/OR ITS AUTHORISED PERSON TO HANDLE ALL MATTERS PERTAINING TO THE SCHEME AND NOTICE OF ANNUAL GENERAL MEETING. Source

  4. Financings

    Share or debt issue: COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE. Source

  5. Financings

    Share or debt issue: PLACING OF NEW SHARES UNDER GENERAL MANDATE. Source

  6. Financings

    Share or debt issue: COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE. Source

  7. Financings

    Share or debt issue: PLACING OF NEW SHARES UNDER GENERAL MANDATE. Source

Press releases

Headlines of Shandong Boan Biotechnology Company., Limited.'s own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN PHASE I CLINICAL TRIAL OF BA1203 (A MASKED ANTI-PD-1/IL-2 FUSION PROTEIN) IN CHINA

  2. HKEXnews

    CONTINUING CONNECTED TRANSACTIONS PROMOTION COOPERATION AGREEMENT

  3. HKEXnews

    VOLUNTARY ANNOUNCEMENT CDE APPROVAL OF IND APPLICATION FOR BA1203 (A MASKED ANTI-PD-1/IL-2 FUSION PROTEIN)

  4. HKEXnews

    SUPPLEMENTAL AGREEMENT IN RELATION TO DISCLOSEABLE TRANSACTION FINANCE LEASE AGREEMENT

  5. HKEXnews

    DISCLOSEABLE TRANSACTION FINANCE LEASE AGREEMENT

  6. HKEXnews

    ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026

  7. HKEXnews

    VOLUNTARY ANNOUNCEMENT CDE ACCEPTANCE OF IND APPLICATION FOR TL1A/IL-23 BISPECIFIC ANTIBODY BA2201

  8. HKEXnews

    VOLUNTARY ANNOUNCEMENT COMPLETION OF PHASE IA CLINICAL TRIAL OF BA1302 (CD228-DIRECTED ADC) IN CHINA

  9. HKEXnews

    INSIDE INFORMATION ANNOUNCEMENT PROFIT WARNING

  10. HKEXnews

    VOLUNTARY ANNOUNCEMENT BLA SUBMISSION FOR AFLIBERCEPT INTRAVITREOUS INJECTION IN BRAZIL

  11. HKEXnews

    VOLUNTARY ANNOUNCEMENT CDE ACCEPTANCE OF IND APPLICATION FOR BA1203 (A MASKED ANTI-PD-1/IL-2 FUSION PROTEIN)

  12. HKEXnews

    VOLUNTARY ANNOUNCEMENT CDE APPROVAL OF PHASE II CLINICAL TRIAL APPLICATION FOR BA1106 IN COMBINATION WITH BA1104 FOR NSCLC

  13. HKEXnews

    POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 22 JUNE 2026

  14. HKEXnews

    VOLUNTARY ANNOUNCEMENT LICENSING OF DULAGLUTIDE INJECTION IN THE U.S.

  15. HKEXnews

    VOLUNTARY ANNOUNCEMENT BLA SUBMISSION FOR TWO DENOSUMAB BIOSIMILARS IN THE U.S.

  16. HKEXnews

    NOTICE OF ANNUAL GENERAL MEETING

  17. HKEXnews

    (1) 2025 REPORT OF THE BOARD OF DIRECTORS (2) 2025 REPORT OF THE BOARD OF SUPERVISORS (3) 2025 ANNUAL REPORT (4) RE-APPOINTMENT OF AUDITOR (5) REMUNERATION OF DIRECTORS (6) REMUNERATION OF SUPERVISORS (7) GENERAL MANDATE TO ISSUE ADDITIONAL SHARES (8) GENERAL MANDATE TO REPURCHASE SHARES (9) PROPOSED ADOPTION OF THE RSU INCENTIVE SCHEME AND PROPOSED AUTHORISATION TO THE BOARD AND/OR ITS AUTHORISED PERSON TO HANDLE ALL MATTERS PERTAINING TO THE SCHEME AND NOTICE OF ANNUAL GENERAL MEETING

  18. HKEXnews

    VOLUNTARY ANNOUNCEMENT BOLUOJIA (DENOSUMAB INJECTION) NEWLY APPROVED IN CHINA FOR TREATING BONE METASTASES FROM SOLID TUMORS AND MULTIPLE MYELOMA

  19. HKEXnews

    VOLUNTARY ANNOUNCEMENT ON-MARKET SHARE REPURCHASE

  20. HKEXnews

    PROPOSED ADOPTION OF RESTRICTED SHARE UNIT INCENTIVE SCHEME

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:6955 on TradingView.

Listing details

Shandong Boan Biotechnology Company., Limited. is a public biotech or pharmaceutical company listed on HKEX under the ticker 6955, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Shandong Boan Biotechnology Company., Limited.
Ticker
6955
Listing
HKEX
Country or territory
China
Business scope
Pharmaceuticals: Major
ISIN
CNE100005RV4
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.